Product Details
Nucala
Mepolizumab100 mg/mL
Solution for Subcutaneous Injection
Single-Use 1-mL Pre-Filled Autoinjector (Preservative-Free)
DIN/PIN/NPN
02492989
Manufacturer
GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care
Formulary Listing Date
2023-04-28
Unit Price
2207.7400
Amount MOH Pays
2207.7400
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
R03DX09
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Asthma | Mepolizumab
For the treatment of severe eosinophilic asthma in adult patients who meet ALL the following criteria:
Initial approval duration: 1 year Renewals will be considered on a case-by-case basis for patients who do not meet any of the following stopping criteria:
|